Skip to content
iCo Therapeutics
  • iCo Therapeutics
  • About Us ▾
    • Our Vision and Strategy
    • Leadership and Board of Directors
    • Accomplishments
  • Current Assets ▾
    • The Problem of Drug Shortages
    • iCo-008
    • Oral Amphotericin B
  • Investor Information
  • Contact
  • iCo Articles

2008 News Releases

2008 News Releases

Nov 18, 2008:

iCo Therapeutics Oral Amphotericin B Poster at AAPS

Nov 17, 2008:

iCo Therapeutics Third Quarter Financial Results

Nov 7, 2008:

iCo Therapeutics Oral Amphotericin B Effective Against Visceral Leishmaniasis

Oct 9, 2008:

iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Pharmacokinetic Results

Oct 1, 2008:

iCo Therapeutics Selected as Canada’s Top 10TM Competition Winner

Sep 29, 2008:

iCo Therapeutics to Present at BioContact Québec

Sep 22, 2008:

iCo Therapeutics Provides Interim Trial Results (Diffuse Diabetic Macular Edema)

Sep 4, 2008:

iCo Therapeutics Outlines Steps to First iCo-009 Human Clinical Trial

Aug 28, 2008:

iCo Therapeutics Second Quarter Financial Results

Jul 8, 2008:

iCo Therapeutics Appoints Mr. Noel Hall and Dr. Christian Fibiger to Board

Jun 26, 2008:

iCo Therapeutics Reports New iCo-009 (Oral Amphotericin B) Preclinical Results

Jun 9, 2008:

iCo Therapeutics Closes $1,140,450 Financing

Jun 2, 2008:

iCo Therapeutics Announces $1,140,450 Financing

May 30, 2008:

iCo Therapeutics First Quarter Financial Results

May 7, 2008:

iCo Therapeutics Acquires Worldwide Rights to iCo-009 (Oral Amphotericin B)

May 5, 2008:

iCo Therapeutics to Present at BioFinance 2008

Apr 28, 2008:

iCo Therapeutics Year-End 2007 Financial Results

Apr 25, 2008:

iCo Therapeutics iCo-007 Diabetic Macular Edema Poster Presentation at ARVO

Apr 21, 2008:

iCo Therapeutics Announces iCo-009 (Oral Amphotericin B) FDA Meeting

Mar 17, 2008:

iCo Therapeutics iCo-009 (Oral Amphotericin B) Published in Leading Drug Delivery Journal

Mar 10, 2008:

iCo Therapeutics Provides iCo-008 Phase II Clinical Update

Feb 27, 2008:

iCo Therapeutics Announces CMO Invited to Present at International Ocular Conference

Jan 21, 2008:

iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Update

Contact Us

 About iCo

 Sitemap

  The Development of Research

© Copyright 2022 - iCo Therapeutics Inc. - All Rights Reserved.